XML 52 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
Equity
 6 Months Ended
Jun. 30, 2017
Equity [Abstract]  
Equity
Equity
Total equity as of June 30, 2017, decreased $555.0 million compared to December 31, 2016. This decrease was primarily driven by share repurchases totaling approximately $1.4 billion, as described below, and an adjustment to retained earnings of $852.8 million reflecting the spin-off of our hemophilia business, as described in Note 3, Hemophilia Spin-Off, to these condensed consolidated financial statements. These decreases were partially offset by net income attributable to Biogen Inc. of $1.6 billion.
Share Repurchases
In July 2016 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2016 Share Repurchase Program). This authorization does not have an expiration date. All share repurchases under this authorization will be retired. Under this program, we repurchased and retired 2.9 million and 3.7 million shares of common stock at a cost of $781.8 million and $1.0 billion during the three and six months ended June 30, 2017, respectively. As of June 30, 2017, approximately $3.0 billion remains available to repurchase shares under this authorization.
In February 2011 our Board of Directors authorized a program to repurchase up to 20.0 million shares of common stock, which was completed as of March 31, 2017. During the six months ended June 30, 2017, we repurchased 1.3 million shares of common stock at a cost of $365.4 million under this program. During the three and six months ended June 30, 2016, we did not repurchase any shares of common stock under this program.
Noncontrolling Interests
The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):
 
For the Three Months
Ended June 30,
 
For the Six Months
Ended June 30,
(In millions)
2017
 
2016
 
2017
 
2016
NCI, beginning of period
$
(11.6
)
 
$
1.3

 
$
(11.5
)
 
$
2.1

Net income (loss) attributable to NCI, net of tax
—

 
(1.4
)
 
(0.1
)
 
(3.1
)
Fair value of net assets and liabilities acquired and assigned to NCI
—

 
—

 
—

 
0.9

NCI, end of period
$
(11.6
)
 
$
(0.1
)
 
$
(11.6
)
 
$
(0.1
)